Pre-treatment with zilovertamab, an anti-ROR1 antibody, blocked Wnt5a’s ability to increase MMP-9 expression and enhance the invasiveness of CLL cells. Here, MMP9 is linked to B-cell chronic lymphocytic leukemia.